Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;25(8):638-650.
doi: 10.2174/0113892037297012240408063250.

Structural Insights of PD-1/PD-L1 Axis: An In silico Approach

Shishir Rohit  1   2 , Mehul Patel  1 , Yogesh Jagtap  2 , Umang Shah  1 , Ashish Patel  1 , Swayamprakash Patel  3 , Nilay Solanki  4
Affiliations

Structural Insights of PD-1/PD-L1 Axis: An In silico Approach

Shishir Rohit et al. Curr Protein Pept Sci. 2024.

Abstract

Background: Interaction of PD-1 protein (present on immune T-cell) with its ligand PD-L1 (over-expressed on cancerous cell) makes the cancerous cell survive and thrive. The association of PD-1/PD-L1 represents a classical protein-protein interaction (PPI), where receptor and ligand binding through a large flat surface. Blocking the PD-1/PDL-1 complex formation can restore the normal immune mechanism, thereby destroying cancerous cells. However, the PD-1/PDL1 interactions are only partially characterized.

Objective: We aim to comprehend the time-dependent behavior of PD-1 upon its binding with PD-L1.

Methods: The current work focuses on a molecular dynamics simulation (MDs) simulation study of apo and ligand bound PD-1.

Results: Our simulation reveals the flexible nature of the PD-1, both in apo and bound form. Moreover, the current study also differentiates the type of strong and weak interactions which could be targeted to overcome the complex formation.

Conclusion: The current article could provide a valuable structural insight about the target protein (PD-1) and its ligand (PD-L1) which could open new opportunities in developing small molecule inhibitors (SMIs) targeting either PD-1 or PD-L1.

Keywords: PD-1/PD-L1 interactions; PD-1: Programmed cell death protein-1; PD-L1: programmed death ligand-1; immune T-cell; molecular dynamics simulations; protein-protein interaction..

PubMed Disclaimer

References

    1. Esfahani K.; Roudaia L.; Buhlaiga N.; Del Rincon S.V.; Papneja N.; Miller W.H.; A review of cancer immunotherapy: From the past, to the present, to the future. Curr Oncol 2020,27(12),87-97 - DOI - PubMed
    1. Pardoll D.M.; The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012,12(4),252-264 - DOI - PubMed
    1. Hoos A.; Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 2016,15(4),235-247 - DOI - PubMed
    1. Khalil D.N.; Smith E.L.; Brentjens R.J.; Wolchok J.D.; The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 2016,13(5),273-290 - DOI - PubMed
    1. Ishida Y.; Agata Y.; Shibahara K.; Honjo T.; Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992,11(11),3887-3895 - DOI - PubMed

MeSH terms